Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Epstein-Barr virus infection following allogeneic hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis

Fig. 1

The impact of letermovir prophylaxis on EBV infections after allo-HCT. A Study flowchart. The cumulative incidences of cs-CMVi (B), EBV DNAemia (C), EBV-disease (D) and PTLD (E) in the letermovir and control groups, respectively. F Cox proportional-hazards analysis for EBV reactivation. DSA: donor-specific antibodies; HID: haploidentical donor; MRD: HLA-matched related donor; MUD: HLA-matched unrelated donor. *EBV DNAemia refers to those patients without EBV-disease/PTLD development

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us